BINZHOU, China – September 4, 2026 – Shandong Binzhou Zhiyuan Biotechnology Co., Ltd. today announced that its Succinyl Chitosan has successfully completed pharmaceutical excipient filing with China’s Center for Drug Evaluation (CDE), under registration number F20260000394.

This filing validates the product’s safety, quality, and regulatory compliance as a pharmaceutical excipient.

Succinyl Chitosan is a water-soluble chitosan derivative featuring excellent biocompatibility and biodegradability. Its anionic charge profile enables stable drug encapsulation, making it suitable for drug delivery systems, wound dressings, and biomedical materials.

The CDE filing (status: “I”) means the product is ready for joint review with drug formulations, offering pharmaceutical companies a documented, regulatory-compliant excipient for innovative drug development.

Shandong Binzhou Zhiyuan Biotechnology Co., Ltd. is a high-tech manufacturer specializing in cyclodextrin and chitosan derivatives for global pharmaceutical, cosmetic, and biomedical markets.

Media Contact:
Tel: +86-543-2616568
Website: www.bzzysw.com